#Sustainability #None #Healthcare Access #WuXi Biologics

WuXi Biologics 2025 Sustainability Report Overview

WuXi Biologics, a prominent player in the global Contract Research, Development, and Manufacturing Organization (CRDMO) sector, recently unveiled its 2025 Sustainability Report. This pivotal document underscores the firm’s dedication to embedding sustainability at the core of its operational strategy. By aligning its business practices with the United Nations Sustainable Development Goals (SDGs), the company is on a mission to enhance healthcare access through innovative solutions.

Commitment to Sustainability

Chief Executive Officer Dr. Chris Chen emphasizes that WuXi Biologics views long-term business success as inseparable from its responsibilities towards society and the environment. As a vanguard in sustainability, the company actively collaborates with stakeholders to foster positive social and environmental effects. Its dedication to providing end-to-end Green CRDMO solutions not only empowers clients but also cultivates responsible practices throughout the entire value chain.

Enhanced Governance Transparency

The sustainability strategy is supported by established governance structures that prioritize transparency and effectiveness. This includes a rigorous, science-based ESG target matrix, which serves as a roadmap tracking performance and facilitating continuous refinement. WuXi Biologics also emphasizes its commitment to ethical practices as an active participant in the Pharmaceutical Supply Chain Initiative (PSCI). In 2025, the company achieved significant certifications, including ISO 20400 Sustainable Procurement certification, thus bolstering supply chain robustness.

Empowering Workforce and Community Engagement

WuXi Biologics celebrates its diverse workforce, comprised of members from 51 distinct nationalities. The company is particularly proud of its efforts to enhance female participation in STEM fields, with women holding 54% of STEM roles. Community service initiatives remain a cornerstone of WuXi's corporate philosophy, exemplified by over 12,000 volunteer hours contributed by employees in local engagements during 2025. These activities not only align with community needs but also reinforce social resilience.

Advancing Healthcare Equity

The company's integrated CRDMO platform is designed to expedite the journey from molecules to patients, enhancing the timely delivery of innovative biologics. By reducing barriers in healthcare accessibility, WuXi Biologics aims to promote equity in health outcomes. The company initiated a significant partnership with Brazil's Instituto Butantan for the commercial manufacturing of a dengue vaccine, reinforcing local public health initiatives.

Focus on Rare Diseases

Addressing the needs of those with rare diseases remains a high priority. WuXi Biologics consistently innovates to develop therapies that improve conditions for patients with rare ailments. The collaboration with CANbridge Pharmaceuticals led to the successful approval of a noteworthy treatment for patients in need, marking an important milestone in rare disease therapies.

Environmental Stewardship Initiatives

WuXi Biologics steps forward in promoting environmental responsibility through ambitious climate action goals and resource efficiency. Notably, in 2025, it set a new and rigorous greenhouse gas emission reduction target, validated by the Science Based Targets initiative (SBTi). The company's Water Excellence Stewardship program aims to cut water intake by 30% from the 2019 baseline, showcasing its commitment to natural resource conservation.

Recognition and Future Aspirations

The efforts made by WuXi Biologics have not gone unnoticed; the firm has earned accolades from various ESG rating agencies, achieving high ratings including an MSCI AAA score and an EcoVadis Platinum Medal. Looking forward to 2026 and beyond, Dr. Chen indicates that the implementation of sustainability will remain central to WuXi Biologics’ growth strategies. Continuing to leverage research, development, and innovative manufacturing capacities, WuXi Biologics is poised to empower its global clients in delivering transformative therapies while contributing to shared prosperity and a healthier society overall.

• ---

WuXi Biologics creates shared value by fostering responsible business practices and innovative solutions. Through its sustainability initiatives, the company aims to cultivate a better future for all stakeholders and redefine what it means to be a global leader in healthcare services.